Colegio Argentino de Cardioangiólogos Intervencionistas Revista Argentina de Cardioangiología intervencionista 2250-7531 2313-9307 4 03 2013 3- 20 Safety and efficacy outcomes among patients with acute coronary syndromes treated with clopidogrel, prasugrel and ticagrelor: insights from randomized clinical trials 0145 0150 EN Gregg W Stone MD, FACC. Professor of Medicine, Columbia University, Director of Cardiovascular Research and Education Center for Interventional Vascular Therapy, New York Presbyterian Hospital/Columbia University Medical Center, Co-Director of Medical Research and Education, The Cardiovascular Research Foundation New York, NY. gstone@crf.org Sorin J Brener MD, FACC. Professor of Medicine - Weill Cornell Medical College and Director, Cardiac Catheterization Laboratory, NY Methodist Hospital, Brooklyn, NY, and The Cardiovascular Research Foundation, New York, NY. Alfredo E Rodríguez MD, FACC. Professor of Medicine, Columbia University, Director of Cardiovascular Research and Education Center for Interventional Vascular Therapy, New York Presbyterian Hospital/Columbia University Medical Center, Co-Director of Medical Research and Education, The Cardiovascular Research Foundation New York, NY. In patients presenting with acute coronary syndromes (with or without ST-segment elevation), dual anti-platelet therapy consisting of aspirin and a platelet ADP-receptor antagonist (P2Y12 inhibitor) is recommended for at least 1 year accorded ACC/AHA guidelines. This recommendation is independent of whether revascularization is performed during the acute hospitalization. The method of revascularization (percutaneous coronary intervention with bare-metal or drug-eluting stents or coronary artery bypass grafting), when performed, does not affect this treatment paradigm either. In the last few years, pivotal randomized clinical trials in patients with acute coronary syndromes compared the first generation agent clopidogrel, with more potent inhibitors (prasugrel and ticagrelor), which have different mechanisms of action and pharmacokinetic properties..The purpose of this review is to compare the study designs and results pertaining to these new compounds and glean insight into the potential advantages and disadvantages of each agent. antiplatelet therapy, acute coronary syndromes, stent thrombosis, thyenopiridines, drug eluting stents http://www.raci.com.ar/contenido/art.php?recordID=MTg0 http://recursos.meducatium.com.ar/contenido/articulos/2601450150_184/pdf/2601450150.pdf